All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Measuring disease modification in MPN clinical trials

Oct 14, 2022
Share:
Learning objective: After reading this article, learners will be able to describe key considerations in measuring disease modification in myeloproliferative neoplasms.

The MPN Hub was pleased to speak to Jean-Jacques Kiladjian, Université de Paris and Hôpital Saint-Louis, Paris, FR and Tiziano Barbui, Papa Giovanni XXIII Hospital, Bergamo, IT. We asked about measuring disease modification in MPN clinical trials. 

Barbui begins by discussing established response criteria and the multi-parameter context of disease modification in myeloproliferative neoplasms, summarizing surrogate and non-surrogate markers. He highlights the complex situation in myelofibrosis compared with polycythemia vera and essential thrombocytosis in this regard.

Kiladjian then raises the challenges around these parameters and opens a discussion on whether artificial intelligence would be useful for a more objective and standardized response assessment in clinical trials.

They also touch upon measuring the molecular response inflammation in disease modification.

Measuring disease modification in MPN clinical trials